Vicore Pharma's CEO describes the rationale for using angiotensin II type 2 receptor agonists in IPF
Ahmed Mousa describes what excited him to join the company from the U.S. one year ago, the unmet need that still exists in this large market, and what the path ahead is for the company's lead asset.
Kommentarer